Cargando…
A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI)‐targeted therapy has emerged as a viable treatment for patients with advanced non‐small cell lung cancer with common EGFR mutations. The uncommon G719X and S768I mutations can co‐occur as complex mutations in the same tumor. Here...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569900/ https://www.ncbi.nlm.nih.gov/pubmed/37614204 http://dx.doi.org/10.1111/1759-7714.15085 |